An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.
Epistemonikos ID: 312c3d6371bb6332f70f4f2c57355e88794b6ed3
First added on: Feb 19, 2024